ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
15 announcements with these filters
Jubilant Pharmova announced the USFDA classified their Spokane facility as 'Voluntary Action Indicated' (VAI) following a recent inspection. This concludes the inspection review process.
Jubilant Pharmova Limited received a GST show cause notice proposing a demand of ₹87.31 Crore. The demand includes tax, interest, and penalties for FY 2022-2023.
Jubilant Pharmova's subsidiary received a GST show-cause notice for Rs. 105.50 Crore. The company is contesting the demand involving GST and an equal penalty.
Jubilant Pharmova held its 48th Annual General Meeting on August 26, 2026, via video conferencing. Shareholders approved all agenda items, including the final dividend declaration.
Jubilant Pharmova received USFDA approval for commercial batch manufacturing on the new Line 3 at its Spokane, U.S.A. contract manufacturing facility.
Jubilant Pharmova shareholders approved the re-appointment of Mr. Priyavrat Bhartia as MD and Mr. Arjun Shanker Bhartia as Joint MD via postal ballot.
Jubilant Pharmova reported Q1 FY27 revenue of ₹2,229 Crore, reflecting 17% YoY growth. Net profit stood at ₹56 Crore amidst margin impacts.
Jubilant Pharmova Ltd reported revenue from operations of ₹2,229 Cr (+17.3% YoY) and net profit of ₹56.4 Cr (-45.0% YoY) for Q1 FY27.
Jubilant Pharmova Limited has issued a notice for its 48th Annual General Meeting, scheduled for August 26, 2026, including the annual report for FY 2025-26.
Jubilant Pharmova Limited has scheduled a Board Meeting on August 07, 2026, to consider and approve the standalone and consolidated financial results for the quarter ended June 30, 2026.
Jubilant Pharmova informed the stock exchanges regarding the communication sent to shareholders concerning the transfer of unclaimed shares and dividends to the IEPF Authority.
Jubilant Pharmova Ltd filed its quarterly shareholding pattern for the period ending June 30, 2026. The filing details the distribution of equity shares across various categories.
Jubilant Pharmova has issued a Postal Ballot Notice seeking shareholder approval for the re-appointment of its Managing Director and Joint Managing Director.
Jubilant Pharmova approved the grant of 2,07,003 Stock Options, RSUs, and PSUs. The exercise prices range from Re. 1 to Rs. 974.45 per share.
Jubilant Pharmova received a rectification order deleting a Rs. 22.10 crore tax demand for AY 2020-21. Separate appeals on other grounds remain pending before ITAT.